Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, ceftaroline fosamil (Zinforo®) cannot be endorsed for use within NHS Wales for the treatment of the following infections in neonates, infants, children and adolescents: complicated skin and soft tissue infections; community-acquired pneumonia. Please refer to the AWMSG position statement on the appraisal of antimicrobial medicines Additional note: AWMSG has previously accepted ceftaroline fosamil for restricted use in adults with suspected methicillin resistant Staphylococcus aureus (MRSA) skin and soft tissue infection and this advice remains in place |
||
|
||
Medicine details |
||
| Medicine name | ceftaroline fosamil (Zinforo®) | |
| Formulation | 600 mg powder for concentrate for solution for infusion | |
| Reference number | 4343 | |
| Indication | For the treatment of the following infections in neonates, infants, children and adolescents: complicated skin and soft tissue infections; community-acquired pneumonia |
|
| Company | Pfizer Ltd | |
| BNF chapter | Infections | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 10/02/2020 | |
| Further information AWMSG position statement on the appraisal of antimicrobial medicines AWMSG has previously accepted ceftaroline fosamil for restricted use in adults with suspected methicillin resistant Staphylococcus aureus (MRSA) skin and soft tissue infection and this advice remains in place. See ceftaroline fosamil (Zinforo®) |
||